Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558669 | 0.90 | CHRM3 (0.41) | CHRM3CHRM2KMT2AMAPTCHRM4 | |
| SCHEMBL4901870 | 0.87 | CYP2B6 (0.45) | CHRM3CHRM2KMT2AMAPTCHRM4 | |
| SCHEMBL18765527 | 0.85 | OPRM1 (0.49) | CHRM3CHRM2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5816021 | 0.80 | CYP2B6 (0.43) | CHRM3CHRM2KMT2AMAPTCHRM4 | |
| SCHEMBL18112743 | 0.77 | CYP2B6 (0.41) | CHRM3CHRM2CHRM1SIGMAR1OPRD1 | |
| SCHEMBL4558785 | 0.76 | KMT2A (0.40) | CHRM3CHRM2KMT2AMAPTCHRM4 | |
| SCHEMBL10760122 | 0.76 | CYP2B6 (0.39) | CHRM3CHRM2KMT2ACHRM4CHRM5 | |
| SCHEMBL12806774 | 0.75 | CHRM2 (0.47) | CHRM3CHRM2KMT2AMAPTCHRM4 | |
| SCHEMBL4559545 | 0.75 | SIGMAR1 (0.44) | CHRM3CHRM2KMT2AMAPTCHRM4 | |
| SCHEMBL4559549 | 0.74 | KMT2A (0.41) | CHRM3CHRM2KMT2AMAPTCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | SIGMAR1, TMEM97, OPRL1 | CHRM3 127/4885CHRM2 283/4885KMT2A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.